A neutrophil activation signature predicts critical illness and mortality in COVID-19
Matthew L. Meizlish, Alexander B. Pine, Jason Bishai, George Goshua, Emily R. Nadelmann, Michael Simonov, C‐Hong Chang, Hanming Zhang, Marcus Shallow, Parveen Bahel, Kent A. Owusu, Yu Yamamoto, Tanima Arora, Deepak Atri, Amisha Patel, Rana Gbyli, Jennifer M. Kwan, Christine Won, Charles S. Dela Cruz, Christina Price, Jonathan L. Koff, Brett King, Henry M. Rinder, F. Perry Wilson, John Hwa, Stephanie Halene, William Damsky, David van Dijk, Alfred Ian Lee, Hyung J. Chun
Abstract
Pathologic immune hyperactivation is emerging as a key feature of critical illness in COVID-19, but the mechanisms involved remain poorly understood. We carried out proteomic profiling of plasma from cross-sectional and longitudinal cohorts of hospitalized patients with COVID-19 and analyzed clinical data from our health system database of more than 3300 patients. Using a machine learning algorithm, we identified a prominent signature of neutrophil activation, including resistin, lipocalin-2, hepatocyte growth factor, interleukin-8, and granulocyte colony-stimulating factor, which were the strongest predictors of critical illness. Evidence of neutrophil activation was present on the first day of hospitalization in patients who would only later require transfer to the intensive care unit, thus preceding the onset of critical illness and predicting increased mortality. In the health system database, early elevations in developing and mature neutrophil counts also predicted higher mortality rates. Altogether, these data suggest a central role for neutrophil activation in the pathogenesis of severe COVID-19 and identify molecular markers that distinguish patients at risk of future clinical decompensation.